Tagged Articles

diabetes drug 74 articles

High-dose diabetes drug Victoza to be sold as obesity drug Saxenda

A high-dose version of Novo Nordisk’s type 2 diabetes drug Victoza, containing the active ingredient liraglutide, has been approved by the Food and Drug Administration (FDA) to treat obesity. The new diet drug will be marketed by Novo Nordisk under the brand name Saxenda. Like Victoza, the new weight loss treatment comes as in injectable drug and is intended for patients with a body mass index (BMI) of 30 or higher and at least one weight-related health condition, such as diabetes. Novo Nordisk believes Saxenda has the potential to be a blockbuster medication, generating sales of more than a billion dollars ... Read More

Drug company tests high doses of type 2 diabetes drug Victoza as possible weight loss treatment

A high-dose version of the type 2 diabetes drug Victoza is being tested as a new diet drug, and studies show it can melt up to 10 percent of body mass. Victoza is currently available in 1.2 mg and 1.8 mg doses to help drive down blood sugar levels in type 2 diabetics. Pre-market studies on the drug already identified weight loss as a side effect of the medication. Thus, the drug’s maker, Novo Nordisk, decided to see if higher doses of Victoza could lead to greater weight loss in obese people without the disease. Novo Nordisk began testing the ... Read More

GSK revamps marketing efforts following record settlement over illegal promotion of drugs

GlaxoSmithKline (GSK) says it will hire doctors to market its drugs to the medical community in an effort to mend its tarnished reputation following a $3 billion fraud settlement over questionable marketing practices. Since 2012, when GSK was accused of illegally promoting its antidepressants Paxil and Wellbutrin and failing to report safety data on its blockbuster diabetes drug Avandia, the drug company has been reforming its marketing efforts to provide more transparency. “We’ll continue to disseminate this very important information on drug benefits and risks, but we’re just not going to do that by hiring external speakers. We want to ... Read More

FDA decision on GSK’s new diabetes treatment delayed

United States drug regulators have pushed back a review of GlaxoSmithKline’s experimental type 2 diabetes drug albiglutide by three months to give more time to for the drug company to submit more data in order for regulators to give a full review. The drug company wouldn’t say if there were any problems identified with the treatment, just that it was complying with Food and Drug Administration (FDA) requests. The FDA decision on whether to approve albiglutide is now April 15, 2014. The drug is still on schedule for review with the European Medicines Agency. Studies showed albiglutide did not control ... Read More

Attorneys investigating cancer cases in patients taking type 2 diabetes drugs

An experimental type 2 diabetes drug vying for Food and Drug Administration (FDA) approval is being tested as an add-on therapy for type 1 diabetes. In January 2012, the FDA declined to approve dapagliflozin, also known by the brand name Forxiga, based on concerns over breast and bladder cancer. The drug’s makers, Bristol-Myers Squibb and AstraZeneca, said they will resubmit the application for approval before the end of the summer. Meanwhile, they are testing the drug for other indications, including a treatment for type 1 diabetes. Currently, type 1 diabetes is typically treated with insulin. Drug makers say dapagliflozin is ... Read More

Indian government bans sale of Actos diabetes drug

Indian drug regulators have suspended sales of the type 2 diabetes drug pioglitazone (known in the United States as Actos), as well as two other drugs – analgin and deanxit – without specifying a reason. Drug companies that market the diabetes drug are taking aim at India’s Drug Technical Advisory Board (DTAB) for the action. “We are demanding a review,” said Indian Pharmaceutical Alliance secretary general D. G. Shah. “A ban has to be based on science and scientific data. It has to follow a proper process and be evaluated by the DTAB and with the knowledge and consultation of ... Read More

Type 2 diabetes drug does not reduce risk of heart attack, stroke, death

Diabetes drug Onglyza (saxagliptin) does not reduce the risk of heart attacks, strokes or death from cardiovascular causes compared to a placebo, drug makers Bristol Myers Squibb and AstraZeneca said. The companies had conducted clinical trials to determine if the Type 2 diabetes treatment could help reduce the risk of non-fatal heart attacks and ischemic strokes and death from cardiovascular problems as well as lower blood glucose levels. Onglyza did not perform better than a placebo; however, it was not inferior to the placebo either. The clinical trials involved 16,500 people with diabetes as well as a history of heart ... Read More

Five years of Actos likely caused plaintiff’s terminal bladder cancer, doctor testifies

A University of Chicago Medical Center urologist told a Los Angeles jury last week that Takeda Pharmaceuticals’ type-2 diabetes drug Actos was “the most substantial causative factor” in a California man’s development of terminal bladder cancer. The doctor’s testimony was part of the first product liability case against Takeda to go to trial over injuries allegedly caused by the blockbuster drug. Plaintiff Jack Cooper, a 79-year-old San Diego area resident, sued Japan-based Takeda after taking Actos for a five-year period from 2006 to 2011. His lawsuit against Takeda was selected as the first of more than 3,000 similar cases to ... Read More

Cost of diabetes rising as number of diabetics increases

The cost of diabetes rose more than 40 percent during the past five years, however the per-patient cost has remained roughly flat, according to new research that will be published in the April issue of Diabetes Care. The study, commissioned by the American Diabetes Association, estimated that diabetes cost the nation $245 billion in 2012, compared to $174 billion in 2007. Comparatively, an estimated 22.3 million people were diagnosed with the disease in 2012, compared to about 17.5 million in 2007. John Anderson, president of medicine and science for the American Diabetes Association, said the data shows the rising cost ... Read More

GSK applies for US, European approval of new type 2 diabetes drug Albiglutide

Months after GlaxoSmithKline (GSK) applied for U.S. approval to market its once-weekly type 2 diabetes drug Albiglutide, the pharmaceutical company has applied to European regulators. GSK is hoping that approval for Albiglutide in the U.S. and Europe will give it opportunity to tap into the growing type 2 diabetes drug market. Albiglutide is in the same class of injectable GLP-1 medications as Byetta and Bydureon, made by Bristol-Myers Squibb and AstraZeneca, and Novo Nordisk’s Victoza, now promoted by celebrity chef Paula Deen. Albiglutide’s road to U.S. Food and Drug Administration (FDA) approval has been winding. Last November, a series of ... Read More